Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)
Funding available for research on HIV cure strategies given at start of ART or ART restart after treatment interruption, aiming for remission without ongoing treatment.
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: January 7, 2025 | May 7, 2025 | September 7, 2025 | January 7, 2026 | May 7, 2026 | September 7, 2026 (AIDS - New/Renewal/Resubmission/Revision)
Funding Amounts: No budget cap; budgets must reflect actual project needs. Maximum project period: 5 years.
Summary: Supports research on HIV cure strategies administered at the start of antiretroviral therapy (ART) or at ART restart after interruption, aiming for sustained, treatment-free remission.
Key Information: Clinical trials are not allowed; use of clinical samples and animal models is encouraged.
Description
This NIH opportunity funds basic and preclinical research to identify and evaluate HIV cure strategies that can be administered at the initiation of combination antiretroviral therapy (cART) or at cART restart following an analytical treatment interruption (ATI). The ultimate goal is to achieve sustained, treatment-free remission of HIV. The program encourages innovative approaches to limit HIV reservoir formation, enhance immune responses, and develop interventions that could be administered at or near the time of ART initiation or restart.
Research may include mechanistic studies, development and testing of experimental interventions (not yet FDA-approved for HIV), and longitudinal studies of viral reservoir dynamics. Use of animal models (HIV, SIV, SHIV) and human clinical samples is encouraged, but clinical trials are not permitted under this funding opportunity.
